Mirtazapine use may increase the risk of hypothyroxinaemia in patients affected by major depressive disorder.

导出原文传递

翻译打印收藏纠错

作者： Ying,Zhao ^[1] ; Na,Wang ^[2] ; Shi Wu,Wen ^[3] ; Mingcan,Li ^[2] ; Yuan,Yuan ^[3] ; Ravi,Retnakaran ^[4] ; Wei,Hao ^[5] ; Ruiling,Zhang ^[6] ; Desheng,Zhai ^[2]

作者单位： The Second Affiliated Hospital, Xinxiang Medical University, Xinxiang, China. ^[1] School of Pharmacy, Xinxiang Medical University, Xinxiang, China. ^[2] Xinxiang Key Laboratory of Clinical psychopharmacology, Xinxiang, China. ^[3] OMNI Research Group, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Canada. ^[4] School of Epidemiology and Public Health, University of Ottawa Faculty of Medicine, Ottawa, Canada. ^[5] Department of Obstetrics, Gynecology, and Newborn Care, University of Ottawa Faculty of Medicine, Ottawa, Canada. ^[6] Division of Endocrinology and Metabolism, University of Toronto, Toronto, Canada. ^[7] Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Canada. ^[8] School of Public Health, Xinxiang Medical University, Xinxiang, China. ^[9] Henan International Joint Laboratory of non-Invasive Neuromodulation, Xinxiang Medical University, Xinxiang, China. ^[10]

关键词 hypothyroxinaemia major depressive disorder mirtazapine structure parameters of thyroid homeostasis thyroid feedback quantile-based index thyroid-stimulating hormone index

主题词抑郁症, 更年期(Depressive Disorder, Major);人类(Humans);发病率(Incidence);回顾性研究(Retrospective Studies)

DOI 10.1111/bcp.14949

PMID 34155670

发布时间 2022-04-11

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交